

Sapacitabine

Catalog No: tcsc0006340



Available Sizes

Size: 5mg

Size: 10mg

Size: 25mg

Size: 50mg

Size: 100mg



Specifications

CAS No:

151823-14-2

Formula:

$C_{26}H_{42}N_4O_5$

Pathway:

Cell Cycle/DNA Damage

Target:

Nucleoside Antimetabolite/Analog

Purity / Grade:

>98%

Solubility:

DMSO : 25 mg/mL (50.95 mM; Need ultrasonic and warming)

Alternative Names:

CS682;CYC682

Observed Molecular Weight:

490.64


Product Description

Sapacitabine is an orally available **nucleoside analog** prodrug that is structurally related to cytarabine.

IC₅₀ & Target: nucleoside analog^[1]

In Vitro: Concentrations of Sapacitabine required to achieve an IC₅₀ range from 3±0.6 µM for the colon cancer cell line HCT116 to 67±14 µM for the breast cancer cell line MDA-MB-435. Cell cycle analysis shows that 35% Sapacitabine-treated cells are arrested in late-S phase and 41% in G₂/M phase. L1210 cells with deoxycytidine kinase (dCK) activity are sensitive to Sapacitabine, (IC₅₀ 20±6 µM). In the docetaxel/Sapacitabine combinations, synergistic effects (CI[1].

In Vivo: On Day 14, the Sapacitabine (5 mg/kg)+vorinostat (33 mg/kg) group has a mean tumour volume of 245 mm³ and a tumour growth inhibition (TGI) of 92%, whereas the Sapacitabine (15 mg/kg)+vorinostat (33 mg/kg) group has a mean tumour volume of 107 mm³ and a TGI of 112%^[2].



All products are for RESEARCH USE ONLY. Not for diagnostic & therapeutic purposes!